About Zentalis

We are focused on the creation of differentiated small molecule treatments targeting fundamental biological pathways of cancer. Using our unique chemistry and biological expertise, we have developed an integrated approach to identify and overcome the limitations of current cancer therapeutics, enabling us to design better small molecules for improved patient outcomes.

Learn More

Pipeline

CompoundComp
IndicationInd
Development ApproachDev
PreclinicalPre
Early Clinical DevelopmentEarly
Late Clinical DevelopmentLate
ZN-c3
Wee1 Inhibitor
Uterine Serous Carcinoma
Monotherapy

ZN-c3
Wee1 Inhibitor

Uterine Serous Carcinoma
Solid Tumors
Monotherapy
Solid Tumors
Cyclin E Driven High Grade Serous Ovarian
Monotherapy
Cyclin E Driven High Grade Serous Ovarian
PARP Resistant Ovarian Cancer
Monotherapy alternating with niraparib or concurrent with niraparib
PARP Resistant Ovarian Cancer
Ovarian Cancer
+ Multiple Chemotherapy Backbones
Ovarian Cancer
Osteosarcoma
+ gemcitabine
Osteosarcoma
BRAF Mutant mCRC
+ encorafenib and cetuximab
BRAF Mutant mCRC
Pancreatic Cancer
+ gemcitabine
Pancreatic Cancer
ZN-d5
BCL-2 Inhibitor
AL Amyloidosis
Monotherapy

ZN-d5
BCL-2 Inhibitor

AL Amyloidosis
NHL
Monotherapy
NHL
AML
+ ZN-c3
AML
BCL-xL
Degrader
Solid Tumors and Heme Malignancies

BCL-xL
Degrader

Solid Tumors and Heme Malignancies

Learn More

Join Zentalis